Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma
Soledad Henriquez, Jérémie Zerbit, Timothée Bruel, Amani Ouedrani, Delphine Planas, P Deschamps, Isabelle Staropoli, Jérôme Hadjadj, Bruno Varet, Natalia Ermak, Didier Bouscary, Lise Willems, Guillemette Fouquet, Justine Decroocq, Patricia Franchi, Bénédicte Deau, Benjamin Terrier, Jérôme Tamburini, Lucienne Chatenoud, Olivier Schwartz, Marguerite Vignon
Abstract
International audience
Topics & Concepts
CD38MedicineMultiple myelomaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Alpha (finance)Immunology2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)VirologyDaratumumabBortezomibInternal medicineBiologyGeneticsStem cellDiseaseConstruct validityInfectious disease (medical specialty)CD34Patient satisfactionNursingOutbreakCalcium signaling and nucleotide metabolismSARS-CoV-2 and COVID-19 ResearchMultiple Myeloma Research and Treatments